Physician profile
Amanda Graham
NPI 1841488491
$1,460.24
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $665 · 2022: $514 · 2023: $258 · 2024: $23.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.61 | 2021-2023 | |
| Amgen INC. | $288.02 | 2021-2023 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $144.45 | 2021-2023 | Rybelsus, Ozempic |
| Medtronic, INC. | $137.88 | 2023 | Resolute Onyx |
| Nestle Healthcare Nutrition INC. | $84.19 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $68.98 | 2021-2023 | Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $55.31 | 2021 | |
| Advanced Respiratory, INC | $54.50 | 2021 | |
| Eisai INC. | $42.49 | 2021 | |
| Mylan Specialty L.P. | $30.66 | 2022-2023 | Yupelri |
| Abbott Laboratories | $23.27 | 2024 | Eterna |
| Biohaven Pharmaceutical Holding Company LTD. | $22.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.04 | 2022 | |
| Biogen, INC. | $17.21 | 2021 | |
| Astellas Pharma US INC | $14.90 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.09 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.